Demographic characteristics of patients at screening (n=121)
| Tiotropium (pm) (n=43) | Tiotropium (am) (n=38) | Placebo (n=40) | Total (n=121) | |
|---|---|---|---|---|
| *Mean (SD). | ||||
| Men (n) | 28 | 21 | 26 | 75 |
| Age (years)* | 66.1 (6.6) | 64.9 (7.7) | 66.5 (9.4) | 65.8 (7.9) |
| Duration of COPD (years)* | 10.0 (8.5) | 12.3 (12.3) | 9.9 (7.9) | 10.7 (9.7) |
| Baseline spirometry:* | ||||
| FEV1 (l) | 1.09 (0.38) | 1.12 (0.45) | 1.04 (0.33) | 1.08 (0.39) |
| FEV1 (% predicted) | 41.8 (14.0) | 41.9 (13.5) | 38.6 (9.6) | 40.8 (12.5) |
| FVC (l) | 2.14 (0.67) | 2.19 (0.68) | 2.15 (0.71) | 2.16 (0.68) |
| FEV1/FVC (%) | 51.8 (11.0) | 50.9 (11.0) | 49.6 (9.3) | 50.8 (10.4) |
| Total taking pulmonary medication during the baseline period | 41 (95.3%) | 36 (94.7%) | 37 (92.5%) | 114 |
| Anticholinergic drugs | 15 (34.9%) | 14 (36.8%) | 18 (45.0%) | 47 |
| Beta adrenergics (inhaled) | 34 (79.1%) | 34 (89.5%) | 35 (87.5%) | 103 |
| Beta adrenergics (oral) | 3 (7.0%) | 4 (10.5%) | 4 (10.0%) | 11 |
| Mucolytic agents | 1 (2.3%) | 3 (7.9%) | 3 (7.5%) | 7 |
| Steroid (inhaled) | 31 (72.1%) | 27 (71.1%) | 27 (67.5%) | 85 |
| Steroid (oral) | 0 (0%) | 0 (0 %) | 2 (5.0%) | 2 |
| Theophylline | 2 (4.7%) | 1 (2.6%) | 2 (5.0%) | 5 |